Search

A recent study from the University of Campania Luigi Vanvitelli in Italy explores the effectiveness of small molecules in treating inflammatory pouch disorders following ileal pouch-anal anastomosis (IPAA) for ulcerative colitis (UC). The researchers found that while biological therapies have shown promise, there is a need for more robust randomized clinical trials. Preliminary studies suggest that Janus kinase (JAK) inhibitors and sphingosine-1-phosphate receptor (S1P-R) modulators, such as Tofacitinib, may be effective in treating chronic pouchitis. However, further evaluation is needed for other small molecules like Upadacitinib, Filgotinib, and ozanimod. The study emphasizes the importance of high-quality studies and real-world registries to develop guidelines for advanced therapies in post-IPAA inflammatory disorders. [Extracted from the article]

A study conducted by researchers at Shiraz University of Medical Sciences in Iran provides an update on the understanding of pouchitis, a common complication after ileal pouch-anal anastomosis (IPAA). The study highlights the need for further research and knowledge in the treatment of pouchitis, which can significantly impact patients' quality of life. The researchers discuss various diagnostic criteria and therapeutic approaches, including antibiotics, probiotics, anti-tumor necrosis factor drugs, dietary changes, and complementary and alternative medicine. They emphasize the importance of well-designed studies to determine the optimal treatment for pouchitis. [Extracted from the article]

A recent study conducted by researchers from the University of North Carolina has found that antibiotic use in the 12 months prior to ileal pouch-anal anastomosis (IPAA) surgery increases the risk of pouchitis, the most common complication after the surgery. The study, which used a population-based cohort of patients in Denmark, found that antibiotic exposure in the year before IPAA was associated with a higher risk of pouchitis. However, nonsteroidal anti-inflammatory drug (NSAID) exposure and appendectomy were not found to be associated with the risk of pouchitis. The researchers suggest that future studies should focus on identifying specific microbial changes in at-risk patients to enable earlier interventions. [Extracted from the article]

A recent study conducted at the Icahn School of Medicine at Mount Sinai in New York City examined the impact of pregnancy on the development of pouchitis in women with ulcerative colitis. Pouchitis is a condition characterized by symptoms such as increased stool frequency and urgency, which are treated with antibiotics. The study found that acute pouchitis was common during pregnancy and the postpartum period, particularly in women with a history of pouchitis. These findings suggest that microbial shifts may contribute to the development of pouchitis during pregnancy. The study highlights the need for preconception counseling to focus on the prevention and management of pouchitis in pregnant women. [Extracted from the article]

Researchers at Tianjin Medical University in China have conducted a study on pouchitis, a common complication following surgery for ulcerative colitis. The researchers created a rat model of pouchitis using microsurgery and induced inflammation in the ileal pouch using dextran sulfate sodium. They validated the success of the model through various analyses. This animal model provides a foundation for further research on the pathogenesis and treatment of pouchitis. [Extracted from the article]

A recent study conducted at Columbia University investigated the association between different surgical techniques used in patients with inflammatory bowel disease (IBD) who underwent restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA). The study found that there was no significant difference in the rates of cuffitis and/or pouchitis between patients who underwent mucosectomy and those who did not. However, patients who underwent mucosectomy were more likely to develop strictures. These findings suggest that stapled anastomosis without mucosectomy may be a preferable technique. [Extracted from the article]

A recent study investigated the association between anti-integrin avb6 antibodies and the development of pouchitis in patients with ulcerative colitis (UC) who underwent restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA). The study found that levels of anti-integrin avb6 antibodies were significantly decreased after RPC, but remained high in patients who developed pouchitis. The antibody levels at the time of RPC may serve as a potential prognostic biomarker for predicting the risk of pouchitis in patients with UC. However, it is important to note that this study has not yet undergone peer review. [Extracted from the article]

A new study conducted at the University of North Carolina Chapel Hill provides insights into the natural history of ulcerative colitis (UC) after ileal pouch-anal anastomosis (IPAA). The study aimed to identify key outcomes within 1, 3, 5, and 10 years after IPAA, including the incidence of pouchitis, Crohn's-like disease of the pouch (CLDP), use of advanced therapies, and pouch failure. The study found that the incidence of pouchitis increased from 58% in the first year after IPAA to 72% at 10 years after IPAA. Additionally, 14% of patients required advanced therapies after IPAA. These findings highlight the ongoing challenges and need for further research in managing UC after IPAA. [Extracted from the article]

A patent application has been submitted for a potential treatment for chronic pouchitis, a condition that affects a significant percentage of patients who have undergone a specific surgical procedure. The cause of pouchitis is believed to be a combination of factors, including exposure to harmful components of feces and immune system dysfunction. Current treatments have had mixed success, so there is a need for more effective therapies. The patent application proposes the use of an anti-a4b7 integrin antibody called vedolizumab, which would be administered to patients with chronic pouchitis to achieve remission and improve symptoms and quality of life. The application provides detailed information on the specific antibody sequences and dosing regimens used in the proposed treatment. [Extracted from the article]

A recent study conducted by researchers at Beth Israel Deaconess Medical Center in Boston, Massachusetts, explores the causes and treatment options for pouchitis, a common complication in patients with inflammatory bowel disease. The study emphasizes the importance of early and accurate diagnosis using a combination of symptoms, endoscopy, and histology. While most patients respond well to antibiotic therapy, managing chronic antibiotic-refractory pouchitis remains challenging. The researchers suggest that further longitudinal assessment of the pouch, incorporating new technologies, may help to better understand the factors driving pouchitis. [Extracted from the article]

A recent study conducted at Columbia University in New York City explores the pathophysiology and management of pouchitis, an inflammatory disease of the ileal reservoir. Pouchitis commonly occurs after restorative proctocolectomy with ileal pouch-anal anastomosis, and treating chronic antibiotic-refractory pouchitis has proven to be challenging. The research highlights the multifactorial nature of pouchitis, involving factors such as genetic disposition, gut microbiota, dysregulated host immunity, surgical techniques, and ischaemia. Diagnosis and classification are crucial for effective management, and treatment options include oral antibiotics for acute pouchitis and induction and maintenance therapy with integrin, interleukin, or tumor necrosis factor inhibitors for chronic antibiotic-refractory pouchitis. Hyperbaric oxygen therapy may be beneficial for chronic pouchitis with ischaemic features, fistulae, or abscesses. [Extracted from the article]

A recent study conducted at the Cleveland Clinic Foundation examined the impact of liver transplantation on patients with primary sclerosing cholangitis and inflammatory bowel disease who also underwent ileal pouch-anal anastomosis (IPAA). The study found that patients who received a liver transplant had a higher rate of chronic pouchitis compared to those who did not receive a transplant. However, overall survival and pouch survival were similar between the two groups. The timing of the liver transplant did not affect the outcomes of the IPAA procedure. The study suggests that liver transplantation does not influence short-term and long-term pouch outcomes in these patients. [Extracted from the article]

A recent study conducted at the University of Tsukuba in Japan explored the association between colonic metaplasia of goblet cells and endoscopic phenotypes of the J pouch in patients with ulcerative colitis (UC). The researchers found that patients with pouchitis showing colonic metaplasia of goblet cells may benefit from early interventions. The study also identified risk factors for diverting ileostomy in UC patients. The findings suggest that greater proportions of sulfomucin-producing goblet cells are observed in endoscopic phenotypes associated with poor outcomes in UC. [Extracted from the article]

A recent study conducted at the University of Ulsan in Korea investigated the risk factors and outcomes of chronic antibiotic-refractory pouchitis (CARP) in Korean patients with ulcerative colitis (UC). The study found that current smokers with UC who underwent total proctocolectomy with ileal pouch-anal anastomosis (IPAA) had a higher risk of developing CARP. Additionally, the use of probiotics was less likely to be associated with CARP development. The study highlights the importance of considering these risk factors and potential interventions for managing CARP in UC patients. [Extracted from the article]

A recent study conducted at Amsterdam University Medical Center explored the efficacy of tofacitinib in treating chronic pouchitis, a condition that affects some ulcerative colitis patients. Thirteen patients with chronic or antibiotic refractory pouchitis were treated with tofacitinib for eight weeks. The study found that 31% of patients achieved clinical remission, while 62% showed a clinical response. However, the study suggests that eight weeks of treatment may be too short to achieve biochemical, endoscopic, or histologic response in these refractory patients. Further research is needed to determine the optimal treatment duration. [Extracted from the article]

A recent study conducted at the University of Leuven in Belgium examined the long-term outcomes of patients with Crohn's disease who underwent modified side-to-side isoperistaltic strictureplasty (SSIS) to treat long strictures in the small intestine. The study aimed to determine if radiological features on MR enterography (MRE) could predict these outcomes. The researchers found that the Simplified MARIA (MARIAs) score, which assesses wall thickness, edema, fat stranding, and ulcers, was not predictive of long-term clinical or surgical recurrence. The study suggests that improvements are needed in scoring tools for predicting outcomes in these patients. [Extracted from the article]

A recent report from the University of North Carolina Chapel Hill discusses the findings of a study on ulcerative colitis. The study aimed to explore the relationship between clinical factors and the incidence of pouchitis, the most common complication after ileal pouch-anal anastomosis (IPAA) surgery for ulcerative colitis. The researchers found that antibiotic exposure in the 12 months prior to IPAA surgery was associated with an increased risk of acute pouchitis. This population-based cohort study suggests the need for future prospective studies to identify specific microbial changes in at-risk patients for earlier interventions. [Extracted from the article]

A recent study conducted at the Cleveland Clinic examined the outcomes of ileal-pouch anal anastomosis (IPAA) in patients with connective tissue disorders. IPAA is a surgical intervention commonly used for patients with ulcerative colitis, familial adenomatous polyposis, and indeterminate colitis. The study found that patients with connective tissue disorders were more likely to experience pouchitis, but there were no significant differences in rates of pouch prolapse or pouch failure compared to control patients. Overall, IPAA remains a viable surgical option for patients with connective tissue disorders, with comparable functional outcomes and quality of life. [Extracted from the article]

A study conducted at the University Hospital in Heraklion, Greece, examined the presence of inflammation in the terminal ileum, a common finding during colonoscopy, even in asymptomatic patients. The study aimed to determine the clinical importance and natural history of this condition, as well as the indications for treatment or follow-up. The retrospective cohort study analyzed data from 107 patients with terminal ileitis as an accidental finding, excluding those with symptoms or known Crohn's Disease. The study found that most patients with incidental, asymptomatic terminal ileitis remained asymptomatic and did not require treatment, but close monitoring is necessary as one-third of them were eventually diagnosed with Crohn's Disease. [Extracted from the article]

A recent study conducted at Weill Cornell Medicine compared two surgical techniques, Kono-S and side-to-side functional end anastomosis, for the treatment of Crohn's disease. The study found that both techniques had similar rates of endoscopic recurrence at 3-6 months after surgery. However, the study also found that smokers had a significantly higher rate of endoscopic recurrence. The research was a prospective multi-center randomized trial conducted at eight international centers and included 288 Crohn's patients. [Extracted from the article]

A recent study conducted by researchers at Washington University in St. Louis focused on ulcerative colitis (UC) and its complications. Specifically, the study examined a subset of patients who develop Crohn's-like disease of the pouch (CDP) after undergoing restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) for UC. The researchers used single-cell analyses to study mucosal cells from patients with and without CDP. The study found distinct cellular and molecular differences between normal pouch/ileum and CDP, including expanded colitogenic immune cells, elevated Th17 signaling, and increased levels of plasma cells, inflammatory fibroblasts, and monocytes in CDP. Additionally, the study identified extensive activation of the unfolded protein response (UPR) in CDP, which was not present in UC, Crohn's disease (CD), or pouchitis. The researchers suggest that these findings could potentially serve as diagnostic markers and therapeutic targets for CDP. [Extracted from the article]

A recent study conducted by researchers at the University of North Carolina has examined the incidence of pouchitis, an inflammatory condition of the pouch, in patients who underwent proctocolectomy with ileal pouch-anal anastomosis (IPAA) for ulcerative colitis (UC). The study found that patients with extraintestinal manifestations of inflammatory bowel disease (IBD) and a family history of IBD were more likely to develop pouchitis within the first 12 months after IPAA. However, the initial antibiotic regimen chosen did not appear to impact long-term outcomes. This research provides valuable insights into the epidemiology and treatment of pouchitis. [Extracted from the article]

A recent study conducted at Mater Hospital Brisbane examined the treatment of chronic pouchitis (CP), a common complication following restorative ileal pouch-anal anastomosis for ulcerative colitis. The study analyzed the efficacy of immunomodulator and biologic therapies for CP by pooling data from various real-world studies. The results showed that the efficacy of these therapies is still poorly defined, but vedolizumab and ustekinumab appeared to be effective and safe for CP treatment. However, further research is needed to determine the comparative effectiveness of available treatments for CP. [Extracted from the article]

The American Gastroenterological Association (AGA) has released the first comprehensive evidence-based guideline on the management of pouchitis, a common complication experienced by people with ulcerative colitis after colon surgery. Pouchitis occurs when the surgically created internal reservoir, or "pouch," becomes inflamed. The guideline provides recommendations for physicians caring for patients with ulcerative colitis who undergo proctocolectomy with ileal pouch-anal anastomosis. It suggests against the use of antibiotics for primary prevention of pouchitis and does not recommend for or against the use of probiotics for prevention. The guideline also outlines four types of inflammatory pouch disorders. Patients with pouchitis can benefit from understanding that it is a real condition with available treatment options. [Extracted from the article]

A recent study conducted by the Helmholtz-Center for Infection Research in Braunschweig, Germany, explored the use of fecal microbiota transplantation (FMT) as a treatment for antibiotic-resistant pouchitis in patients with ulcerative colitis (UC). The researchers analyzed the gut metatranscriptomes of three patients and their donors before and after FMT. They found that FMT led to a temporary increase in metabolic activities associated with health, such as the biosynthesis of amino acids and butyrate. However, the study emphasizes the need for further research and validation in larger cohorts before FMT can be widely used. The researchers suggest that probiotics with high taxonomic diversity could be a potential alternative to FMT in the long run. [Extracted from the article]

Keywords: Antimetabolites; Antineoplastics; Cancer; Capecitabine Therapy; Chemotherapy; Digestive System Diseases and Conditions; Drugs and Therapies; Enteritis; Gastroenteritis; Gastroenterology; Gastrointestinal Diseases and Conditions; Health and Medicine; Ileal Diseases and Conditions; Ileitis; Oncology; Pharmaceuticals; Rectal Cancer; Risk and Prevention EN Antimetabolites Antineoplastics Cancer Capecitabine Therapy Chemotherapy Digestive System Diseases and Conditions Drugs and Therapies Enteritis Gastroenteritis Gastroenterology Gastrointestinal Diseases and Conditions Health and Medicine Ileal Diseases and Conditions Ileitis Oncology Pharmaceuticals Rectal Cancer Risk and Prevention 1578 1578 1 10/30/23 20231103 NES 231103 2023 OCT 31 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- New study results on rectal cancer have been published. Antimetabolites, Antineoplastics, Cancer, Capecitabine Therapy, Chemotherapy, Digestive System Diseases and Conditions, Drugs and Therapies, Enteritis, Gastroenteritis, Gastroenterology, Gastrointestinal Diseases and Conditions, Health and Medicine, Ileal Diseases and Conditions, Ileitis, Oncology, Pharmaceuticals, Rectal Cancer, Risk and Prevention. [Extracted from the article]

Biologic therapy was considered appropriate in most scenarios (14/16) and uncertain in situations where significant prepouch ileitis or CD-like complications were absent (2/16). Keywords: Los Angeles; State:California; United States; North and Central America; Crohn's Disease; Digestive System Diseases and Conditions; Drugs and Therapies; Enteritis; Enterostomy; Gastroenteritis; Gastrointestinal Diseases and Conditions; Health and Medicine; Ileal Diseases and Conditions; Ileitis; Ileostomy; Pouchitis; Surgery EN Los Angeles State:California United States North and Central America Crohn's Disease Digestive System Diseases and Conditions Drugs and Therapies Enteritis Enterostomy Gastroenteritis Gastrointestinal Diseases and Conditions Health and Medicine Ileal Diseases and Conditions Ileitis Ileostomy Pouchitis Surgery 1011 1011 1 10/30/23 20231103 NES 231103 2023 NOV 3 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- A new study on Digestive System Diseases and Conditions - Crohn's Disease is now available. [Extracted from the article]

Digestive System Diseases and Conditions, Enteritis, Gastroenteritis, Gastrointestinal Diseases and Conditions, Health and Medicine, Ileal Diseases and Conditions, Ileitis, Pouchitis Keywords: Digestive System Diseases and Conditions; Enteritis; Gastroenteritis; Gastrointestinal Diseases and Conditions; Health and Medicine; Ileal Diseases and Conditions; Ileitis; Pouchitis EN Digestive System Diseases and Conditions Enteritis Gastroenteritis Gastrointestinal Diseases and Conditions Health and Medicine Ileal Diseases and Conditions Ileitis Pouchitis 139 139 1 09/25/23 20230925 NES 230925 2023 SEP 25 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Devices & Surgical Technology Week -- Fresh data on pouchitis are presented in a new report. Keywords for this news article include: Department of Internal Medicine, Austell, Georgia, United States, North and Central America, Ileitis, Pouchitis, Gastroenteritis, Health and Medicine, Ileal Diseases and Conditions, Digestive System Diseases and Conditions, Gastrointestinal Diseases and Conditions. [Extracted from the article]

In the established CD-like ileitis SAMP mouse model, direct skip lesion injection of nMSCs prevents ileal skip lesion growth and significantly down-regulates the pro-inflammatory milieu. Keywords: Chicago; State:Illinois; United States; North and Central America; Cardiology; Crohn's Disease; Digestive System Diseases and Conditions; Drugs and Therapies; Enteritis; Gastroenteritis; Gastrointestinal Diseases and Conditions; Health and Medicine; Ileal Diseases and Conditions; Ileitis; Inflammation; Mesenchymal Stem Cells; Pharmaceuticals; Placebos; Stem Cell Research EN Chicago State:Illinois United States North and Central America Cardiology Crohn's Disease Digestive System Diseases and Conditions Drugs and Therapies Enteritis Gastroenteritis Gastrointestinal Diseases and Conditions Health and Medicine Ileal Diseases and Conditions Ileitis Inflammation Mesenchymal Stem Cells Pharmaceuticals Placebos Stem Cell Research 207 207 1 08/21/23 20230825 NES 230825 2023 AUG 21 (NewsRx) -- By a News Reporter-Staff News Editor at Stem Cell Week -- Research findings on Digestive System Diseases and Conditions - Crohn's Disease are discussed in a new report. [Extracted from the article]

Keywords: Amebicides; Antibacterials; Antibiotics; Antiinfectives; Antiprotozoal Agents; Ciprofloxacin Therapy; Combination Therapy; Dermatological Agents; Digestive System Diseases and Conditions; Drugs and Therapies; Enteritis; Gastroenteritis; Gastrointestinal Diseases and Conditions; Health and Medicine; Ileal Diseases and Conditions; Ileitis; Metronidazole Therapy; Nitroimidazoles; Ophthalmic Antiinfectives; Ophthalmic Preparations; Otic Antiinfectives; Otic Preparations; Pharmaceuticals; Pouchitis; Quinolones Therapy; Topical Acne Agents EN Amebicides Antibacterials Antibiotics Antiinfectives Antiprotozoal Agents Ciprofloxacin Therapy Combination Therapy Dermatological Agents Digestive System Diseases and Conditions Drugs and Therapies Enteritis Gastroenteritis Gastrointestinal Diseases and Conditions Health and Medicine Ileal Diseases and Conditions Ileitis Metronidazole Therapy Nitroimidazoles Ophthalmic Antiinfectives Ophthalmic Preparations Otic Antiinfectives Otic Preparations Pharmaceuticals Pouchitis Quinolones Therapy Topical Acne Agents 2329 2329 1 08/07/23 20230807 NES 230807 2023 AUG 11 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on pouchitis. We sought to evaluate the comparative effectiveness of ciprofloxacin monotherapy, metronidazole monotherapy, and combination therapy (ciprofloxacin and metronidazole) in the treatment of an initial episode of pouchitis after ileal pouch-anal anastomosis (IPAA) for ulcerative colitis (UC).". [Extracted from the article]

Colitis, Colonic Diseases and Conditions, Digestive System Diseases and Conditions, Drugs and Therapies, Enteritis, Gastroenteritis, Gastroenterology, Gastrointestinal Diseases and Conditions, Health and Medicine, Ileitis, Immunotherapy, Inflammation, Inflammatory Bowel Diseases and Conditions, Monoclonal Antibodies, Pharmaceuticals, Pouchitis, Surgery, Ulcerative Colitis, Ileal Diseases and Conditions, Vedolizumab Therapy, University of Oxford Keywords: Colitis; Colonic Diseases and Conditions; Digestive System Diseases and Conditions; Drugs and Therapies; Enteritis; Gastroenteritis; Gastroenterology; Gastrointestinal Diseases and Conditions; Health and Medicine; Ileal Diseases and Conditions; Ileitis; Immunotherapy; Inflammation; Inflammatory Bowel Diseases and Conditions; Monoclonal Antibodies; Pharmaceuticals; Pouchitis; Surgery; Ulcerative Colitis; University of Oxford; Vedolizumab Therapy EN Colitis Colonic Diseases and Conditions Digestive System Diseases and Conditions Drugs and Therapies Enteritis Gastroenteritis Gastroenterology Gastrointestinal Diseases and Conditions Health and Medicine Ileal Diseases and Conditions Ileitis Immunotherapy Inflammation Inflammatory Bowel Diseases and Conditions Monoclonal Antibodies Pharmaceuticals Pouchitis Surgery Ulcerative Colitis University of Oxford Vedolizumab Therapy 1211 1211 1 04/17/23 20230418 NES 230418 2023 APR 21 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- 12% of people with ulcerative colitis need surgery to have their colon removed (colectomy). Vedolizumab is available for treatment of ulcerative colitis and Crohn's disease in the UK, Europe and around the world'. [Extracted from the article]

Zhejiang, People's Republic of China, Asia, Biomedicine, Digestive System Diseases and Conditions, Drugs and Therapies, Enteritis, Gastroenteritis, Gastrointestinal Diseases and Conditions, Health and Medicine, Ileal Diseases and Conditions, Ileitis, Immunosuppressive Agents, Kidney Transplants, Mycophenolate Mofetil Therapy, Organ Transplants, Pharmaceuticals, Surgery, Transplant Medicine, Transplantation Keywords: Zhejiang; People's Republic of China; Asia; Biomedicine; Digestive System Diseases and Conditions; Drugs and Therapies; Enteritis; Gastroenteritis; Gastrointestinal Diseases and Conditions; Health and Medicine; Ileal Diseases and Conditions; Ileitis; Immunosuppressive Agents; Kidney Transplants; Mycophenolate Mofetil Therapy; Organ Transplants; Pharmaceuticals; Surgery; Transplant Medicine; Transplantation EN Zhejiang People's Republic of China Asia Biomedicine Digestive System Diseases and Conditions Drugs and Therapies Enteritis Gastroenteritis Gastrointestinal Diseases and Conditions Health and Medicine Ileal Diseases and Conditions Ileitis Immunosuppressive Agents Kidney Transplants Mycophenolate Mofetil Therapy Organ Transplants Pharmaceuticals Surgery Transplant Medicine Transplantation 267 267 1 04/10/23 20230413 NES 230413 2023 APR 13 (NewsRx) -- By a News Reporter-Staff News Editor at Blood Weekly -- Current study results on Digestive System Diseases and Conditions - Ileitis have been published. [Extracted from the article]

Keywords for this news article include: Western University, Ileitis, Pouchitis, Gastroenteritis, Health and Medicine, Ileal Diseases and Conditions, Digestive System Diseases and Conditions, Gastrointestinal Diseases and Conditions. Keywords: Digestive System Diseases and Conditions; Enteritis; Gastroenteritis; Gastrointestinal Diseases and Conditions; Health and Medicine; Ileal Diseases and Conditions; Ileitis; Pouchitis EN Digestive System Diseases and Conditions Enteritis Gastroenteritis Gastrointestinal Diseases and Conditions Health and Medicine Ileal Diseases and Conditions Ileitis Pouchitis 2023 FEB 13 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Devices & Surgical Technology Week -- Investigators publish new report on pouchitis. [Extracted from the article]